Andrianto, Mia Puspitasari, Meity Ardiana, Ivana Purnama Dewi, Khubay Alvia Shonafi, Louisa Fadjri Kusuma Wardhani, Ricardo Adrian Nugraha
{"title":"通过血流介导的舒张内皮功能参数测量单核苷酸多态性SLCO1B1基因与辛伐他汀多效效应的关系","authors":"Andrianto, Mia Puspitasari, Meity Ardiana, Ivana Purnama Dewi, Khubay Alvia Shonafi, Louisa Fadjri Kusuma Wardhani, Ricardo Adrian Nugraha","doi":"10.1177/17539447221132367","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Atherosclerosis is a condition in which the medium to large arteries become inflamed over time. The cornerstone to the atherosclerosis process is endothelial dysfunction. Simvastatin is a cholesterol-lowering drug known for its endothelial cell pleiotropic properties. The role of genetic polymorphisms in simvastatin-resistance difficulties has recently piqued people's interest. This problem is thought to be linked to the pleiotropic action of simvastatin, particularly in terms of restoring endothelial function. The goal of this study is to see if there is a link between the single nucleotide polymorphism (SNP) c.521T>C and the pleiotropic effect of simvastatin as determined by the endothelial function parameter, flow-mediated dilation (FMD).</p><p><strong>Methods: </strong>This research was a multicentre cross-sectional study including 71 hypercholesterolemia patients who have been on simvastatin for at least 3 months. The real-time polymerase chain reaction identified SNP c.521T>C. The right brachial artery ultrasonography was used to measure FMD.</p><p><strong>Results: </strong>In 71 hypercholesterolemia patients, the SNP c.521T>C was found in 9.9% of them. On χ<sup>2</sup> analysis, there was no significant association between SNP c.521T>C (TC genotype) and FMD (<i>p</i> = 0.973). On logistic regression analysis, the duration of simvastatin medication was linked with an increased incidence (Adj. OR (adjusted odds ratio) = 2.424; confidence interval (CI) = 1.117-5.260, <i>p</i> = 0.025) and a reduction in systolic blood pressure (Adj. OR = 0.92; CI = 0.025-0.333, <i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>There was no association between FMD and the SNP c.521T>C (TC genotype). The duration of simvastatin medication and systolic blood pressure were both associated to FMD.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/55/10.1177_17539447221132367.PMC9629567.pdf","citationCount":"1","resultStr":"{\"title\":\"Association between single nucleotide polymorphism SLCO1B1 gene and simvastatin pleiotropic effects measured through flow-mediated dilation endothelial function parameters.\",\"authors\":\"Andrianto, Mia Puspitasari, Meity Ardiana, Ivana Purnama Dewi, Khubay Alvia Shonafi, Louisa Fadjri Kusuma Wardhani, Ricardo Adrian Nugraha\",\"doi\":\"10.1177/17539447221132367\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Atherosclerosis is a condition in which the medium to large arteries become inflamed over time. The cornerstone to the atherosclerosis process is endothelial dysfunction. Simvastatin is a cholesterol-lowering drug known for its endothelial cell pleiotropic properties. The role of genetic polymorphisms in simvastatin-resistance difficulties has recently piqued people's interest. This problem is thought to be linked to the pleiotropic action of simvastatin, particularly in terms of restoring endothelial function. The goal of this study is to see if there is a link between the single nucleotide polymorphism (SNP) c.521T>C and the pleiotropic effect of simvastatin as determined by the endothelial function parameter, flow-mediated dilation (FMD).</p><p><strong>Methods: </strong>This research was a multicentre cross-sectional study including 71 hypercholesterolemia patients who have been on simvastatin for at least 3 months. The real-time polymerase chain reaction identified SNP c.521T>C. The right brachial artery ultrasonography was used to measure FMD.</p><p><strong>Results: </strong>In 71 hypercholesterolemia patients, the SNP c.521T>C was found in 9.9% of them. On χ<sup>2</sup> analysis, there was no significant association between SNP c.521T>C (TC genotype) and FMD (<i>p</i> = 0.973). On logistic regression analysis, the duration of simvastatin medication was linked with an increased incidence (Adj. OR (adjusted odds ratio) = 2.424; confidence interval (CI) = 1.117-5.260, <i>p</i> = 0.025) and a reduction in systolic blood pressure (Adj. OR = 0.92; CI = 0.025-0.333, <i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>There was no association between FMD and the SNP c.521T>C (TC genotype). The duration of simvastatin medication and systolic blood pressure were both associated to FMD.</p>\",\"PeriodicalId\":23035,\"journal\":{\"name\":\"Therapeutic Advances in Cardiovascular Disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/55/10.1177_17539447221132367.PMC9629567.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Cardiovascular Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/17539447221132367\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Cardiovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17539447221132367","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1
摘要
背景:动脉粥样硬化是一种中大动脉随着时间的推移而发炎的情况。动脉粥样硬化过程的基础是内皮功能障碍。辛伐他汀是一种降胆固醇药物,以其内皮细胞多效性而闻名。基因多态性在辛伐他汀耐药困难中的作用最近引起了人们的兴趣。这个问题被认为与辛伐他汀的多效性作用有关,特别是在恢复内皮功能方面。本研究的目的是观察单核苷酸多态性(SNP) C . 521t >C与辛伐他汀的多效效应之间是否存在联系,这是由内皮功能参数血流介导的扩张(FMD)决定的。方法:本研究是一项多中心横断面研究,包括71例服用辛伐他汀至少3个月的高胆固醇血症患者。实时聚合酶链反应鉴定SNP C. 521t >C。采用右肱动脉超声测量FMD。结果:71例高胆固醇血症患者中,SNP C . 521t >C占9.9%。经χ2分析,SNP C . 521t >C (TC基因型)与口蹄疫无显著相关性(p = 0.973)。经logistic回归分析,辛伐他汀用药持续时间与发病率增加相关(Adj. OR(校正优势比)= 2.424;可信区间(CI) = 1.117-5.260, p = 0.025)和收缩压降低(OR = 0.92;CI = 0.025-0.333, p = 0.001)。结论:口蹄疫与SNP C . 521t >C (TC基因型)无相关性。辛伐他汀治疗持续时间和收缩压均与FMD相关。
Association between single nucleotide polymorphism SLCO1B1 gene and simvastatin pleiotropic effects measured through flow-mediated dilation endothelial function parameters.
Background: Atherosclerosis is a condition in which the medium to large arteries become inflamed over time. The cornerstone to the atherosclerosis process is endothelial dysfunction. Simvastatin is a cholesterol-lowering drug known for its endothelial cell pleiotropic properties. The role of genetic polymorphisms in simvastatin-resistance difficulties has recently piqued people's interest. This problem is thought to be linked to the pleiotropic action of simvastatin, particularly in terms of restoring endothelial function. The goal of this study is to see if there is a link between the single nucleotide polymorphism (SNP) c.521T>C and the pleiotropic effect of simvastatin as determined by the endothelial function parameter, flow-mediated dilation (FMD).
Methods: This research was a multicentre cross-sectional study including 71 hypercholesterolemia patients who have been on simvastatin for at least 3 months. The real-time polymerase chain reaction identified SNP c.521T>C. The right brachial artery ultrasonography was used to measure FMD.
Results: In 71 hypercholesterolemia patients, the SNP c.521T>C was found in 9.9% of them. On χ2 analysis, there was no significant association between SNP c.521T>C (TC genotype) and FMD (p = 0.973). On logistic regression analysis, the duration of simvastatin medication was linked with an increased incidence (Adj. OR (adjusted odds ratio) = 2.424; confidence interval (CI) = 1.117-5.260, p = 0.025) and a reduction in systolic blood pressure (Adj. OR = 0.92; CI = 0.025-0.333, p = 0.001).
Conclusion: There was no association between FMD and the SNP c.521T>C (TC genotype). The duration of simvastatin medication and systolic blood pressure were both associated to FMD.
期刊介绍:
The journal is aimed at clinicians and researchers from the cardiovascular disease field and will be a forum for all views and reviews relating to this discipline.Topics covered will include: ·arteriosclerosis ·cardiomyopathies ·coronary artery disease ·diabetes ·heart failure ·hypertension ·metabolic syndrome ·obesity ·peripheral arterial disease ·stroke ·arrhythmias ·genetics